Hyponatremia, or low serum sodium levels, is a common electrolyte imbalance that can have serious complications if left untreated. It is estimated that between 10-20% of hospitalized patients have hyponatremia. It is especially common among elderly patients, who are more likely to suffer from multiple comorbidities that can contribute to the condition. Euvolemic hyponatremia, which is characterized by normal total body water and sodium levels, is the most common type of hyponatremia seen in clinical practice. In this article, we will discuss the pathophysiology of euvolemic hyponatremia, as well as the current treatment strategies and emerging therapies. We will also discuss the importance of early diagnosis and management in order to reduce the risk of serious complications.
Euvolemic hyponatremia is caused by an imbalance between the rate of water intake and the rate of water excretion. It is most commonly caused by a defect in the body's ability to excrete water, such as in the case of Syndrome of Inappropriate Antidiuretic Hormone (SIADH). In SIADH, the body is unable to excrete excess water, leading to an accumulation of water in the body and a decrease in serum sodium levels. Other causes of euvolemic hyponatremia include psychogenic polydipsia, diuretic therapy, and certain medications. In addition, certain medical conditions, such as liver cirrhosis, congestive heart failure, and renal failure, can lead to euvolemic hyponatremia.
The primary goal of treatment for euvolemic hyponatremia is to restore the serum sodium level to a safe range. This can be accomplished through a combination of lifestyle modifications, medications, and intravenous fluids. Lifestyle modifications such as reducing fluid intake, avoiding alcohol, and increasing salt intake can help to reduce the severity of symptoms. Medications such as diuretics, vasopressin receptor antagonists, and loop diuretics can help to reduce the amount of water in the body and restore normal serum sodium levels. Intravenous fluids can also be used to replace lost electrolytes and restore normal sodium levels.
In recent years, researchers have been exploring new therapeutic strategies for the treatment of euvolemic hyponatremia. One such strategy is the use of the vasopressin antagonist tolvaptan. Tolvaptan is a selective, non-peptide V2 receptor antagonist that has been shown to be effective in increasing serum sodium levels in patients with euvolemic hyponatremia. In addition, researchers are exploring the use of hypertonic saline to treat euvolemic hyponatremia. Hypertonic saline can rapidly increase serum sodium levels and has been shown to be safe and effective in clinical trials.
Euvolemic hyponatremia is a common electrolyte imbalance that can have serious complications if left untreated. The primary goal of treatment is to restore the serum sodium level to a safe range. Current treatment strategies include lifestyle modifications, medications, and intravenous fluids. In addition, researchers are exploring new therapeutic strategies, such as the use of vasopressin antagonists and hypertonic saline. Early diagnosis and management of euvolemic hyponatremia is essential in order to reduce the risk of serious complications.
1.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
2.
Some triple negative breast cancers might be avoided by longer breastfeeding
3.
Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy
4.
FDA Greenlights First Engineered Cell Therapy for a Solid Tumor
5.
Headlines About Doc Who 'Catches' Patient's Cancer Are Popping Up Again
1.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
2.
Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy
3.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
4.
Optimizing Oncology Practice Revenue: Billing Software, Payer Trends, and Financial Navigation Tools
5.
Mastering Surgical Oncology: Education, Certification, Trials, and Therapy Insights
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation